[1] 陈娟, 王小红. 恩替卡韦与干扰素联合抗乙型肝炎病毒治疗进展. 肝脏, 2016, 21:145-148.
[2] 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2010年版). 中华内科杂志, 2011, 3:66-82.
[3] Yang J, Chen G, Chen X, et al. Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure. Virol J, 2015, 12:97-102.
[4] Seto WK, Hui AJ, Wong VW, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut, 2015, 64:667-672.
[5] 赖玺杰, 连江山, 陈涧阳, 等. 拉米夫定和阿德福韦酯初始联合治疗慢性乙型肝炎和乙型肝炎肝硬化患者替换为恩替卡韦单药治疗的疗效和安全性观察. 中华肝脏病杂志, 2018, 26:113-118.
[6] Srivastava M, Singh N, Dixit VK, et al. Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study. Ndian J Med Res, 2016, 144:424-432.
[7] Shimizu M, Furusyo N, Ikezaki H, et al. Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. World J Gastroentero, 2015, 21:2116-2123.
[8] Wong GL, Tse YK, Wong VW, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology, 2015, 62:684-693. |
